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A comprehensive inventory of TLX1 controlled long
non-coding RNAs in T-cell acute lymphoblastic
leukemia through polyA+ and total RNA sequencing
T-cell acute lymphoblastic leukemia (T-ALL) is an
aggressive hematological malignancy arising from uncon-
trolled proliferation and arrested differentiation of pre-
cursor T-cells. T-ALL is a genetically heterogeneous dis-
ease and can be subdivided into different molecular cyto-
genetic subgroups associated with specific gene expres-
sion signatures.1,2 The T-cell leukemia homeobox 1
(TLX1, HOX11) transcription factor is a key driver of the
TLX subgroup in T-ALL with ectopic expression in devel-
oping thymocytes causing a maturation arrest at the early
cortical stage of T-cell development. Aberrant TLX1
expression occurs in 5-10 % of pediatric and 30 % of
adult T-ALL patients and predominantly results from
t(7;10)(q34;q24) or t(10;14)(q24;q11) chromosomal
translocations leading to juxtaposition of TLX1 to the T-
cell receptor (TCR) d or β promoter.3 The TLX1 gene reg-
ulatory network has been extensively studied in terms of
co-factors and downstream protein-coding gene targets.4
Given that the protein-coding part of the genome only
constitutes about 2 % while up to 70 % of the genome is
transcribed (as non-coding ribonucleic acid (RNA)), a
deeper exploration of the TLX1 driven non-coding tran-
scriptome in T-ALL is warranted to support a more pro-
found understanding of the molecular basis of this T-ALL
subtype.5 Long non-coding RNAs (lncRNAs) recently
emerged as crucial transcriptional regulators in normal
development and cancer, including normal and malignant
hematopoiesis.6,7 LncRNAs are arbitrarily defined as tran-
scripts longer than 200 nucleotides and are poorly evolu-
tionary conserved in terms of sequence.8 Recently, our
lab has identified a subset of lncRNAs that act in concert
with NOTCH1 in both normal T-cell development and
malignant T-cell transformation and a set of T-ALL sub-
group-specific lncRNAs using microarray data.9,10 In this
study, we performed in vitro TLX1 knockdown in T-ALL
cells as well as a deep exploration of the TLX subgroup-
specific lncRNAome in primary T-ALLs. For the former,
we applied an integrative genomics approach combining
quantitative data on the transcriptome and immunopre-
cipitated and open chromatin, using RNA-sequencing
(RNA-seq), chromatin immunoprecipitation sequencing
(ChIP-seq) and assay for transposase-accessible chro-
matin sequencing (ATAC-seq), respectively. Using this
approach, we identified known and novel lncRNAs and
gained insight into the super-enhancer marked lncRNA
genetic landscape in TLX driven T-ALL, amongst others.
To elucidate the lncRNA repertoire under control of the
TLX1 transcription factor, we performed transient TLX1
knockdown by electroporating two TLX1 targeting small
interfering RNAs (siRNAs) in ALL-SIL lymphoblasts, dis-
playing ectopic TLX1 expression as a result of a
t(10;14)(q24;q11) translocation. From the resulting tran-
scriptomes, both polyA+ and total RNA-seq libraries
were generated in order to evaluate the expression
changes of polyadenylated as well as non-polyadenylat-
ed lncRNA transcripts (Online Supplementary Figure
S1A,B). By combining lncRNAs (biotype 'lincRNA' or
'antisense') detected with polyA+ (Figure 1A, left) and
total RNA-seq (Figure 1A, right), more lncRNAs were sig-
nificantly (adjusted P-value <0.05) downregulated (146
lncRNAs) than upregulated (80 lncRNAs) upon TLX1
knockdown (Online Supplementary Table S1). Up- or
downregulation of nine of the top ten differentially
TLX1-regulated lncRNAs detected by polyA+ and total
RNA-seq could be validated by quantitative reverse tran-
scription polymerase chain reaction (RT-qPCR) (Online
Supplementary Figure S2). Of note, this significantly differ-
ent ratio between up- and downregulated lncRNAs is
contrary to the effect of TLX1 knockdown on protein-
coding genes (mainly upregulated upon TLX1 knock-
down) (Online Supplementary Figure S3A), in concordance
with its previously described role as a transcriptional
repressor.4 Moreover, this opposite ratio remains intact
upon integration of TLX1 ChIP-seq data (Online
Supplementary Figure S3B). Using de novomotif analysis on
transcriptionally active (H3K27Ac+) and inactive
(H3K27Ac-) TLX1 bound regions, a significant enrich-
ment for the RUNX, PBX and MEIS family of transcrip-
tion factor motifs was observed for H3K27ac+ and
H3K27ac- regions, as previously observed for TLX1-reg-
ulated protein-coding genes.4 In contrast, some transcrip-
tion factors such as SP1 and TGIF1 were only enriched in
H3K27ac+ or H3K27ac- regions, suggesting that TLX1
activated genes can be transcriptionally regulated by dif-
ferent transcription factor families compared to TLX1
repressed genes (Figure 1B). 
Among the 226 lncRNAs regulated by TLX1, 64
lncRNAs display a TLX1 chromatin binding peak in their
immediate vicinity (max. 5 kb) (Online Supplementary
Table S1), as illustrated for lncRNA RP11-539L10.2
(Online Supplementary Figure S4A). For 80 of the 226 dif-
ferentially regulated lncRNAs upon TLX1 knockdown,
the expression was significantly correlated with at least
one neighboring protein-coding gene (|rho|(Rs) >0.5, 
P-value <0.05) located within a 100 kb window, irrespec-
tive of strand orientation (Online Supplementary Table S2).
From the latter, 97.25 % are positively correlated with
the expression of the differentially regulated lncRNAs,
consistent with previous reports.11 
Interestingly, three of the identified TLX1-regulated
lncRNAs are in the vicinity (max 1 Mb) of a known dif-
ferentially regulated T-ALL tumor suppressor gene4
(Online Supplementary Figure S4B,C; Online Supplementary
Table S1 and S3). To assign a possible function to the top
five TLX1 up- and downregulated lncRNAs, a guilt-by-
association approach was followed as described in the
Online Supplementary Methods section of this paper (Online
Supplementary Figure S5 and S6). 
As it is known that some lncRNAs are located within
super-enhancer regions, a hockey stick plot based on
H3K27ac ChIP data for lncRNA loci was generated as
described in Online Supplementary Methods (Figure 1C).
Among the 2781 super-enhancer associated lncRNAs,
115 lncRNAs were significantly differentially expressed
upon TLX1 knockdown with a significant enrichment (42
lncRNAs) of TLX1 binding for these TLX1-regulated,
super-enhancer associated lncRNAs, as exemplified for
lncRNA NBAT1 (Figure 1D; Online Supplementary Table
S1). As super-enhancers are associated with regions of
open chromatin, we also performed ATAC-seq and con-
firmed that 98.95 % of the super-enhancer regions over-
lap with regions of open chromatin. Moreover, we dis-
covered that 66.4 % of the transcription start sites (TSSs)
from highly expressed (top decile) genes had ATAC-seq
peaks within +/- 5 kb (Online Supplementary Figure S7). To
further explore the functional association of super-
enhancers and expressed lncRNAs, the genome-wide
transcriptional response of lncRNAs upon JQ1 treatment
of ALL-SIL lymphoblasts was investigated, given that this
bromodomain and extra-terminal motif (BET) inhibitor
causes a decrease in the expression of super-enhancer
associated genes (Online Supplementary Figure S8A).12
Among 115 super-enhancer associated, TLX1-regulated
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lncRNAs, 41 lncRNAs were differentially expressed upon
JQ1 inhibition (Online Supplementary Table S1). Moreover,
26 upregulated and 24 downregulated lncRNAs upon
TLX1 knockdown were significantly overlapping with
those lncRNAs downregulated upon JQ1 exposure
(Online Supplementary Figure S8B). 
In addition to previously annotated genes, 2788
lncRNAs that have not been previously annotated in
Ensembl, Gencode, LNCipedia and RefSeq were also
detected. Of these novel lncRNAs, 82 are differentially
regulated upon TLX1 knockdown, of which 30 are direct-
ly bound by TLX1, as illustrated for MSTRG.6968 (Figure
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Figure 1. Integrative TLX1 ChIP-
seq and transcriptome analysis
upon TLX1 knockdown in ALL-SIL
lymphoblasts for identification
of a robust set of TLX1 directly
regulated lncRNAs and super-
enhancer associated lncRNAs.
(A) Volcano plot representation of
differentially expressed lncRNAs
upon TLX1 knockdown in ALL-SIL.
Red (upregulated upon TLX1
knockdown) and blue (downregu-
lated upon TLX1 knockdown)
dots represent significantly differ-
entially expressed lncRNAs
detected with polyA+ RNA-seq
(left panel) and total RNA-seq
(right panel) (adjusted P-value
<0.05). LncRNA names depicted
in the plots are the top ten differ-
entially regulated lncRNAs.
Outliers with a -log10(padj) >30
are scaled to log10(padj)=30. (B)
Motif enrichment analysis on the
set of TLX1 bound regions with
and without overlap of H3K27ac
ChIP-seq peaks using MEME-
ChIP suite identifies significant
enrichment of the DNA binding
motifs of the RUNX, PBX and
MEIS family of transcription fac-
tors for both sets of peaks while
the SP1 and TGIF1 families are
only enriched in one set of peaks.
(C) Hockey stick plot representing
the normalized rank and cluster
signal of clusters of H3K27ac
ChIP-seq peaks at lncRNA tran-
scripts. Red dots represent
lncRNAs significantly associated
with a super-enhancer (adjusted
P-value <0.05). (D) IGV screen-
shot of a super-enhancer associ-
ated lncRNA (NBAT1). PolyA+ and
total RNA-seq tracks are depicted
for control siRNA transfected
samples. Bars represent the
MACS2 peaks with FDR <0.05.





2A,B; Online Supplementary Table S4). Of note,
MSTRG.37538 is a lncRNA marked with one of the
strongest genome-wide super-enhancer sites of all identi-
fied unannotated lncRNAs (Figure 2C,D).
In a complementary approach, TLX1 and TLX3 (fur-
ther denoted as TLX) driven lncRNAs were retrieved
from a primary T-ALL patient cohort as TLX1 and TLX3
induce T-ALL in a similar way and are associated with a
similar gene expression profile.13 By using polyA+ RNA-
seq data of 60 T-ALL patients (including 17 TLX positive
cases) as well as total RNA-seq of 25 T-ALL patients
(including 10 TLX positive cases) 442 known and 158
novel TLX subgroup-specific lncRNAs were identified
(Figure 3A; Online Supplementary Figure S9 and S10A;
Online Supplementary Table S5 and S6). From these, 32
known and 14 novel lncRNAs overlapped significantly
with the known and novel set of differentially expressed
genes upon TLX1 knockdown, respectively (Figure 3B;
Online Supplementary Figure S10B). Moreover, 22 known
and three novel TLX subgroup-specific lncRNAs are in
the vicinity (max 1 Mb) of a known differentially regulat-
ed T-ALL tumor suppressor gene (Online Supplementary
Table S5 and S6).4 






Figure 2. Identification of a set
of previously unannotated
TLX1 regulated lncRNAs in
ALL-SIL lymphoblasts. (A)
Volcano plot representation of
unannotated differentially
expressed lncRNAs upon TLX1
knockdown in ALL-SIL. Red
(upregulated upon TLX1 knock-
down) and blue (downregulated
upon TLX1 knockdown) dots
represent significantly differen-
tially expressed lncRNAs
detected with polyA+ RNA-seq
(left panel) and total RNA-seq
(right panel) (adjusted P-value
<0.05). Gene names depicted
in the plots are the top ten
unannotated differentially regu-
lated lncRNAs. (B) IGV screen-
shot of an unannotated differ-
entially expressed, TLX1 bound
lncRNA (MSTRG.6968). PolyA+
and total RNA-seq tracks are
depicted for control siRNA
transfected samples. Bars rep-
resent the MACS2 peaks with
FDR <0.05. (C) Hockey stick
plot representing the normal-
ized rank and cluster signal of
clusters of H3K27ac ChIP-seq
peaks. Red dots represent
unannotated lncRNAs signifi-
cantly associated with a super-




total RNA-seq tracks are depict-
ed for control siRNA transfect-
ed samples. Bars represent the
MACS2 peaks with FDR <0.05.
RNA: ribonucleic acid. lncRNA:
long non-coding RNA.
lncRNAs, this new data was integrated with our previ-
ously generated polyA+ RNA-seq data of OP9-DL1 cul-
tured T-cells,10 serving as reference material for lncRNA
expression levels in untransformed T-cell progenitors.
Therefore, lncRNAs that are significantly higher
expressed in the TLX subgroup as compared to the other
T-ALL subgroups of the primary T-ALL cohort (HOXA,
immature, TAL) and significantly higher as compared to
normal T-cells were selected. Those lncRNAs that were
also differentially expressed among any of the other 
T-ALL subgroups and T-cells were excluded. In total, 144
TLX-specific, potentially oncogenic lncRNAs were iden-
tified (Figure 3C), as illustrated for lncRNA RP11-
973H7.4 (Figure 3D, left), located in the immediate vicin-
ity of the well-known T-ALL tumor suppressor gene
PTPN2 (Figure 3D, right). 
In this study, we present the first comprehensive analy-
sis of the lncRNA transcriptome of TLX1+ ALL-SIL lym-
phoblasts and TLX subtype primary T-ALLs, uniquely
integrating the polyadenylated and non-polyadenylated
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Figure 3. Identification of TLX
specific, possibly oncogenic
lncRNAs in a primary T-ALL
cohort. (A) Volcano plot repre-
sentation of lncRNAs that are
significantly higher or lower in
the TLX group as compared with
T-ALL patients belonging to
other T-ALL subtypes (TALR,
immature, HOXA). Red (upregu-
lated in TLX subtype T-ALLs ver-
sus other subtypes) and blue
(downregulated in TLX subtype
T-ALLs versus other subtypes)
dots represent significantly dif-
ferentially expressed lncRNAs
detected with polyA+ RNA-seq
(left) and total RNA-seq (right)
(adjusted P-value <0.05).
LncRNA names depicted in the
plots are the top ten differen-
tially regulated lncRNAs. (B)
Venn diagram depicting the
overlap between significant dif-
ferentially expressed lncRNAs
upon TLX1 knockdown and TLX
subgroup specific lncRNAs
(Fisher’s exact test, adjusted P-
value =1.601e-12). (C) Volcano
plot representation of lncRNAs
that are significantly higher
expressed in the TLX group as
compared with normal T-cell
subsets. Gray and red dots rep-
resent significant differentially
expressed lncRNAs (adjusted P-
value <0.05). Red dots are TLX
specific lncRNAs not differen-
tially expressed between T-cells
and other subgroups. LncRNA
names depicted in the plots are
the top five differentially regu-
lated lncRNAs. (D) Boxplot and
IGV screenshot for lncRNA
RP11-973H7.4, that is signifi-
cantly higher expressed in the
TLX subgroup compared to the
other subgroups and signifi-
cantly higher expressed as in
normal thymocytes. PolyA+ and
total RNA-seq tracks are depict-
ed for control siRNA transfected
samples. Bars represent the
MACS2 peaks with FDR <0.05.






transcriptome and chromatin features. Our results reveal
that TLX1 directly regulates a set of known and novel
lncRNAs of which some are marked by super-enhancers.
By integrating normal T-cell data and a primary T-ALL
patient cohort, we also identified 144 putative TLX-spe-
cific oncogenic lncRNAs, which could be further tested
for phenotypic effects upon knockdown and explored as
new targets for RNA-based therapeutics. LncRNAs may
serve as excellent therapeutic targets as these are often
expressed in a cell-type-specific manner, offering poten-
tial advantages with respect to on-target toxicity as
shown by our research group for lncRNA SAMMSON in
melanoma.14 In conclusion, our study delineates a TLX
subgroup and TLX1-specific lncRNA network including a
subset of super-enhancer associated lncRNAs. Our work,
together with that of others, strongly suggest an impor-
tant role of lncRNAs in T-ALL and warrant further func-
tional investigation.9,10,15 
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